A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Latest Information Update: 17 Jan 2022
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Cardiovascular disorders; Coronary artery disease; Decompensated heart failure; Myocardial infarction; Stroke; Thrombosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms COMMANDER-HF
- Sponsors Bayer; Janssen Research & Development; Janssen-Cilag
- 01 Jan 2022 Results published in the Clinical Research in Cardiology
- 03 Aug 2021 Results of systematic review and meta-analysis fom COMMANDER HF, ATLAS ACS 2-TIMI 51 and COMPASS; evaluating efficacy and safety of rivaroxaban in patients with coronary artery disease, heart failure and sinus rhythm, published in the European Journal of Clinical Pharmacology
- 17 May 2021 Results of Meta-Analysis from Atlas-ACS-2 TIMI-51, COMMANDER HF, COMPASS and VOYAGER PAD; assessing whether low-dose Rivaroxaban is associated with reduction in ischemic outcomes but with increased bleeding, presented at the 70th Annual Scientific Session of the American College of Cardiology